Hence, Treg immunosuppressive role has been described in giloblastoma patients (tumour recurrence and poor prognosis) [392] and in CRC patients [393], inhibiting effector T cells (Table 2). fight off and defeat possible attacks or infections. Nevertheless, sometimes this threat comes from an internal factor. Situations such as the existence of a tumour also cause our … Continue reading Hence, Treg immunosuppressive role has been described in giloblastoma patients (tumour recurrence and poor prognosis) [392] and in CRC patients [393], inhibiting effector T cells (Table 2)